Navigation Links
BIO Ventures for Global Health Receives $7 Million Grant from Gates Foundation to Engage Biotechnology in the Fight Against Neglected Diseases of the Developing World
Date:10/14/2008

-Funds to support creation of market incentives and facilitate new R&D collaborations-

WASHINGTON, Oct. 14 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health (BVGH) today announced that the Bill & Melinda Gates Foundation has expanded its support of the organization, so it can further engage biotechnology industry innovation to create new medicines for infectious diseases of the developing world. The $7 million grant will help BVGH build the market case for biotechnology industry investment through market-based incentives and to create new opportunities for R&D collaborations.

"We are thrilled by the Bill & Melinda Gates Foundation's support for expanding the BVGH mission," said Christopher D. Earl, PhD, President and CEO of BVGH. "Biotechnology industry resources are integral to the discovery of new solutions for the millions of patients suffering from diseases such as malaria, tuberculosis and African sleeping sickness."

Barriers such as insufficient markets, funding, and information continue to deter industry from applying their technologies to research and development for neglected tropical diseases (NTDs). BVGH is tackling these barriers and addressing the issues most often identified by both the public and private sectors as limiting collaboration and the application of biotechnology resources.

"The biotech industry has an exceptional opportunity to apply its innovative skills to create new global health solutions," said Tachi Yamada, MD, President of the Gates Foundation's Global Health Program. "BVGH designs economic incentives and partnerships that help make this industry commitment possible."

BVGH's accomplishments are measured by the growing numbers of companies who are committing their best scientists and technologies to solving the most pressing public health needs across the globe.

"Improving health care in developing nations is a goal that all biotechnology companies share," said Joshua Boger, Ph.D., President and CEO of Vertex Pharmaceuticals Incorporated, and Chairman of the Biotechnology Industry Organization (BIO). "Biotechnology innovation has dramatically changed the lives of millions of people worldwide, and our industry must remain committed to utilizing its expertise and resources to ensure that diseases of both the developed and developing world are addressed in new and more effective ways."

About Bio Ventures for Global Health

BIO Ventures for Global Health (BVGH), a non-profit organization, is harnessing the resources of the biotechnology industry to create new medicines for neglected diseases of the developing world. Our mission is to break down barriers that hinder industry involvement in global health product development and to catalyze new industry investment. http://www.bvgh.org


'/>"/>
SOURCE BIO Ventures for Global Health
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Hank Plain Joins Morgenthaler Ventures as Partner
2. Dan Broderick Joins Prolog Ventures as Partner
3. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures
4. Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence
5. Khosla Ventures and BIOeCON Form KiOR Inc.
6. Jerusalem Global Ventures Announces $200 Million Growth Equity Fund
7. 5AM Ventures Announces Expansion of Investment Team: Names Richard Ulevitch Venture Partner; Promotes Kevin Forrest and Andrew McMillan to Principal
8. Clarus Ventures Closes $660 Million Fund
9. The Bill & Melinda Gates Foundation, BIO, and Bio Ventures for Global Health Invite Proteome Systems CEO to Speak on TB Diagnostics Solutions At Partnering for Global Health Forum, Washington D.C.
10. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
11. SPO Medical Retains American Capital Ventures for Investor Relations Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , ... December 08, 2016 , ... ... FrontPanel SDK that provide essential device-to-computer interconnect using USB or PCI Express, announced ... FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a ...
(Date:12/8/2016)... , ... December 08, 2016 ... ... the commercial launch of flexible packaging for their exceptionally efficient human mesenchymal ... system extends RoosterBio’s portfolio of bioprocess media products engineered to radically streamline ...
(Date:12/8/2016)... Fla. , Dec. 8, 2016  HedgePath ... company that discovers, develops and plans to commercialize ... its shares of common stock were approved for ... will begin trading on the OTCQX, effective today, ... qualify for the OTCQX market, companies must meet ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
Breaking Biology Technology:
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, Inc. ... therapeutics focused on the gut microbiome, today announced ... 25,000,000 shares of its common stock and warrants ... at a price to the public of $1.00 ... Synthetic Biologics from the offering, excluding the proceeds, ...
Breaking Biology News(10 mins):